Homozygous 2p21 Microdeletion Syndrome C5679912
Homozygous 2p21 microdeletion syndrome is a rare genetic disorder involving deletion of a small region on chromosome 2. This can affect multiple body systems and development. Management requires specialized care addressing individual symptoms.
Key facts at a glance
- ICD-10
- Q89.9
- ICD-11
- LA00.0
- Body system
- congenital
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Seizures
Generalized symptoms
(congenital)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Developmental delay
(developmental)Facial dysmorphism
(craniofacial)Renal anomalies
(renal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Methionine-restricted diet
Lifelong dietary restriction of methionine intake through specialized meal planning. Treatment requires consultation with metabolic nutrition specialists to ensure adequate overall nutrition while limiting toxic amino acid accumulation.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Pyridoxine supplementation trial
Vitamin B6 supplementation trial to assess responsiveness, as some patients with homocystinuria features may benefit from increased B6 cofactor availability for cystathionine beta-synthase.
Additional treatment options
Betaine supplementation
Betaine serves as an alternative methyl donor to lower homocysteine levels through remethylation pathways. Particularly useful in patients with residual enzyme activity.
medicationFolic acid and B12 supplementation
Co-factor supplementation to support homocysteine metabolism through remethylation pathways. Often used in combination with other therapies for optimal homocysteine control.
medicationMetabolic laboratory surveillance
Regular monitoring of plasma total homocysteine, methionine, and amino acid levels to assess treatment efficacy and adjust dietary and pharmacological interventions accordingly.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Homozygous 2p21 Microdeletion Syndrome C5679912?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Homozygous 2p21 Microdeletion Syndrome C5679912. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy